U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End-use, And Segment Forecasts, 2023 - 2030

Market Segmentation 

• U.S. Clinical Oncology Next Generation Sequencing Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing Centrifuges
• U.S. Clinical Oncology Next Generation Sequencing Workflow Outlook (Revenue, USD Million, 2018 - 2030)
  • Pre-Sequencing
  • Sequencing
  • Data Analysis
• U.S. Clinical Oncology Next Generation Sequencing Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Screening
    • Sporadic Cancer
    • Inherited Cancer
  • Companion Diagnostics
  • Other Diagnostics
• U.S. Clinical Oncology Next Generation Sequencing End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Clinics
  • Laboratories

U.S. Clinical Oncology Next Generation Sequencing Market Dynamics

Driver: Growing related advancement of personalized medicine

One of the most important factors, which is expected to have a significant impact on clinical oncology NGS market, is that how much and to what extent the growth of personalized medicine will enhance adoption of NGS in the coming years. The exponentially decreasing cost of sequencing whole genomes with the subsequent technological advancement of precision medicine in a way replicates Moore’s law for semiconductors in the field of life sciences. Owing to this reduction in prices, NGS will witness a growth in demand in applications of clinical diagnostics in cancer. Depending upon the development of regulatory framework for safety and efficacy of NGS-based lab tests and increasing clinical investigation data on disease-heterogeneity, it is expected that growth in demand for precision medicine is expected to have a pull effect for the U.S. oncology next generation sequencing market over the forecast period.

Driver: Rise in competition amongst prominent market entities

This industry is marked by high competition between the dominant players, strategies adopted include the launch of novel platforms that are rapid, small with respect to size, and less expensive to enhance market presence. Furthermore, companies are increasing the installation base by providing the sequencing services in different countries of Latin America and Asia Pacific. These players are also involved in capitalizing on the product development and marketing in order to maintain significant share of the industry. Acquisition of the smaller entities operating in the market is also one of the strategic initiatives adopted by the players in order to maintain market presence.

Restraint: Lack of computational efficiency for data management

Translation of the obtained sequenced data into conclusive biological insights is of utmost importance, which can be carried out by efficient data management tools. Decreasing cost of sequencing and increasing number of sequence reads being generated are placing greater demand on the computational resources and knowledge necessary to handle sequence data. Sequencing platform installation involves the large-fixed cost associated with purchasing of a machine followed by low variable costs for actual running of the machine. On the contrary, cloud computing and its associated concepts, such as platform, software, and infrastructure as a service, remove the need for such large initial fixed-cost investment. However, the variable costs associated with access to cloud computing are found to be significantly higher, thereby restraining the adoption rate of NGS technique in the clinical settings and diagnostic laboratories. Absence of data management and abstraction tools with the following parameters is attributive for impeding the implementation of NGS based data for translational research in clinical oncology.

What Does This Report Include?

This section will provide insights into the contents included in this u.s. clinical oncology next generation sequencing market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

U.S. clinical oncology next generation sequencing market qualitative analysis

• Industry overview

• Industry trends

• Market drivers and restraints

• Market size

• Growth prospects

• Porter’s analysis

• PESTEL analysis

• Key market opportunities prioritized

• Competitive landscape

  • Company overview

  • Financial performance

  • Product benchmarking

  • Latest strategic developments

U.S. clinical oncology next generation sequencing market quantitative analysis

• Market size, estimates, and forecast from 2018 to 2030

• Market estimates and forecast for product segments up to 2030

• Regional market size and forecast for product segments up to 2030

• Market estimates and forecast for application segments up to 2030

• Regional market size and forecast for application segments up to 2030

• Company financial performance